{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:56:08Z","timestamp":1790873768723,"version":"4.1.0"},"reference-count":54,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T00:00:00Z","timestamp":1554681600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministerio de Ciencia, Innovaci\u00f3n e Universidades","award":["SAF2016-79040-R"],"award-info":[{"award-number":["SAF2016-79040-R"]}]},{"name":"Ministerio de Ciencia, Innovaci\u00f3n e Universidades","award":["SAF2014-52361-R"],"award-info":[{"award-number":["SAF2014-52361-R"]}]},{"name":"Ministerio de Ciencia, Innovaci\u00f3n e Universidades","award":["SAF2017-83267-C2-1-R"],"award-info":[{"award-number":["SAF2017-83267-C2-1-R"]}]},{"DOI":"10.13039\/100012818","name":"Comunidad de Madrid","doi-asserted-by":"crossref","award":["B2017\/BMD-3733 Immunothercan"],"award-info":[{"award-number":["B2017\/BMD-3733 Immunothercan"]}],"id":[{"id":"10.13039\/100012818","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD16\/0015\/0018-REEM"],"award-info":[{"award-number":["RD16\/0015\/0018-REEM"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009513","name":"Fondation Acteria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009513","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008666","name":"Fundaci\u00f3 la Marat\u00f3 de TV3","doi-asserted-by":"crossref","award":["201723"],"award-info":[{"award-number":["201723"]}],"id":[{"id":"10.13039\/100008666","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100011199","name":"FP7 Ideas: European Research Council","doi-asserted-by":"publisher","award":["ERC-2016-Consolidator Grant 725091"],"award-info":[{"award-number":["ERC-2016-Consolidator Grant 725091"]}],"id":[{"id":"10.13039\/100011199","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Commission H2020","award":["635122-PROCROP H2020"],"award-info":[{"award-number":["635122-PROCROP H2020"]}]},{"name":"European Commission H2020","award":["635122-PROCROP H2020"],"award-info":[{"award-number":["635122-PROCROP H2020"]}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004410","name":"European Molecular Biology Organization","doi-asserted-by":"publisher","award":["ALTF 438-2016"],"award-info":[{"award-number":["ALTF 438-2016"]}],"id":[{"id":"10.13039\/100004410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003176","name":"Ministerio de Educaci\u00f3n, Cultura y Deporte","doi-asserted-by":"publisher","award":["FPU16\/03142"],"award-info":[{"award-number":["FPU16\/03142"]}],"id":[{"id":"10.13039\/501100003176","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0565-5","type":"journal-article","created":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T08:02:39Z","timestamp":1554710559000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":127,"title":["Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen"],"prefix":"10.1136","volume":"7","author":[{"given":"Stefanie K.","family":"Wculek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Amores-Iniesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Conde-Garrosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sof\u00eda C.","family":"Khouili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Melero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2890-3984","authenticated-orcid":false,"given":"David","family":"Sancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,4,8]]},"reference":[{"key":"565_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fimmu.2018.00014","volume":"9","author":"A Durgeau","year":"2018","unstructured":"Durgeau A, Virk Y, Corgnac S, Mami-Chouaib F. Recent advances in targeting CD8 T-cell immunity for more effective Cancer immunotherapy. Front Immunol. 2018;9:14.","journal-title":"Front Immunol"},{"key":"565_CR2","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.cell.2016.08.052","volume":"166","author":"M Singer","year":"2016","unstructured":"Singer M, Wang C, Cong L, Marjanovic ND, Kowalczyk MS, Zhang H, et al. A distinct gene module for dysfunction uncoupled from activation in tumor-infiltrating T cells. Cell. 2016;166:1500\u201311.","journal-title":"Cell"},{"key":"565_CR3","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350\u20135.","journal-title":"Science"},{"key":"565_CR4","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1158\/1078-0432.CCR-16-0049","volume":"22","author":"TL Whiteside","year":"2016","unstructured":"Whiteside TL, Demaria S, Rodriguez-Ruiz ME, Zarour HM, Melero I. Emerging opportunities and challenges in Cancer immunotherapy. Clin Cancer Res. 2016;22:1845\u201355.","journal-title":"Clin Cancer Res"},{"key":"565_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.trecan.2017.12.007","volume":"4","author":"M Saxena","year":"2018","unstructured":"Saxena M, Bhardwaj N. Re-emergence of dendritic cell vaccines for Cancer treatment. Trends Cancer. 2018;4:119\u201337.","journal-title":"Trends Cancer"},{"key":"565_CR6","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrclinonc.2014.111","volume":"11","author":"I Melero","year":"2014","unstructured":"Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol. 2014;11:509\u201324.","journal-title":"Nat Rev Clin Oncol"},{"key":"565_CR7","first-page":"197","volume":"36","author":"E Anassi","year":"2011","unstructured":"Anassi E, Ndefo UA. Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer. P T. 2011;36:197\u2013202.","journal-title":"P T"},{"key":"565_CR8","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.it.2017.05.006","volume":"38","author":"AD Garg","year":"2017","unstructured":"Garg AD, Coulie PG, Van den Eynde BJ, Agostinis P. Integrating next-generation dendritic cell vaccines into the current Cancer immunotherapy landscape. Trends Immunol. 2017;38:577\u201393.","journal-title":"Trends Immunol"},{"key":"565_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.coi.2017.06.003","volume":"47","author":"M Saxena","year":"2017","unstructured":"Saxena M, Bhardwaj N. Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines. Curr Opin Immunol. 2017;47:35\u201343.","journal-title":"Curr Opin Immunol"},{"key":"565_CR10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3389\/fimmu.2014.00165","volume":"5","author":"F Wimmers","year":"2014","unstructured":"Wimmers F, Schreibelt G, Sk\u00f6ld AE, Figdor CG, De Vries IJM. Paradigm shift in dendritic cell-based immunotherapy: from in vitro generated monocyte-derived DCs to naturally circulating DC subsets. Front Immunol. 2014;5:165.","journal-title":"Front Immunol"},{"key":"565_CR11","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1080\/21645515.2016.1197453","volume":"12","author":"S Boudewijns","year":"2016","unstructured":"Boudewijns S, Bloemendal M, Gerritsen WR, de Vries IJM, Schreibelt G. Dendritic cell vaccination in melanoma patients: from promising results to future perspectives. Hum Vaccin Immunother. 2016;12:2523\u20138.","journal-title":"Hum Vaccin Immunother"},{"key":"565_CR12","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1158\/1078-0432.CCR-15-1399","volume":"22","author":"KF Bol","year":"2016","unstructured":"Bol KF, Schreibelt G, Gerritsen WR, de Vries IJM, Figdor CG. Dendritic cell-based immunotherapy: state of the art and beyond. Clin Cancer Res. 2016;22:1897\u2013906.","journal-title":"Clin Cancer Res"},{"key":"565_CR13","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3390\/biomedicines3040282","volume":"3","author":"S Sittig","year":"2015","unstructured":"Sittig S, de Vries I, Schreibelt G. Primary human blood dendritic cells for Cancer immunotherapy\u2014tailoring the immune response by dendritic cell maturation. Biomedicines. 2015;3:282\u2013303.","journal-title":"Biomedicines"},{"key":"565_CR14","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.trecan.2018.09.001","volume":"4","author":"JP B\u00f6ttcher","year":"2018","unstructured":"B\u00f6ttcher JP, Reis E Sousa C. The role of type 1 conventional dendritic cells in Cancer immunity. Trends Cancer. 2018;4:784\u201392.","journal-title":"Trends Cancer"},{"key":"565_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/imm.12888","volume":"154","author":"M Collin","year":"2018","unstructured":"Collin M, Bigley V. Human dendritic cell subsets: an update. Immunology. 2018;154:3\u201320.","journal-title":"Immunology"},{"key":"565_CR16","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1158\/0008-5472.CAN-12-2583","volume":"73","author":"J Tel","year":"2013","unstructured":"Tel J, Aarntzen EHJG, Baba T, Schreibelt G, Schulte BM, Benitez-Ribas D, et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res. 2013;73:1063\u201375.","journal-title":"Cancer Res"},{"key":"565_CR17","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1158\/1078-0432.CCR-15-2205","volume":"22","author":"G Schreibelt","year":"2016","unstructured":"Schreibelt G, Bol KF, Westdorp H, Wimmers F, Aarntzen EHJG, Duiveman-de Boer T, et al. Effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid dendritic cells. Clin Cancer Res. 2016;22:2155\u201366.","journal-title":"Clin Cancer Res"},{"key":"565_CR18","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1084\/jem.20100348","volume":"207","author":"A Bachem","year":"2010","unstructured":"Bachem A, G\u00fcttler S, Hartung E, Ebstein F, Schaefer M, Tannert A, et al. Superior antigen cross-presentation and XCR1 expression define human CD11c + CD141 + cells as homologues of mouse CD8 + dendritic cells. J Exp Med. 2010;207:1273\u201381.","journal-title":"J Exp Med"},{"key":"565_CR19","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1084\/jem.20100223","volume":"207","author":"K Crozat","year":"2010","unstructured":"Crozat K, Guiton R, Contreras V, Feuillet V, Dutertre C-A, Ventre E, et al. The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8\u03b1 + dendritic cells. J Exp Med. 2010;207:1283\u201392.","journal-title":"J Exp Med"},{"key":"565_CR20","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1084\/jem.20092140","volume":"207","author":"SL Jongbloed","year":"2010","unstructured":"Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, et al. Human CD141 + (BDCA-3) + dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med. 2010;207:1247\u201360.","journal-title":"J Exp Med"},{"key":"565_CR21","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1084\/jem.20092618","volume":"207","author":"LF Poulin","year":"2010","unstructured":"Poulin LF, Salio M, Griessinger E, Anjos-Afonso F, Craciun L, Chen J-L, et al. Characterization of human DNGR-1 + BDCA3 + leukocytes as putative equivalents of mouse CD8\u03b1 + dendritic cells. J Exp Med. 2010;207:1261\u201371.","journal-title":"J Exp Med"},{"key":"565_CR22","doi-asserted-by":"publisher","first-page":"xii44","DOI":"10.1093\/annonc\/mdx237","volume":"28","author":"AR S\u00e1nchez-Paulete","year":"2017","unstructured":"S\u00e1nchez-Paulete AR, Teijeira A, Cueto FJ, Garasa S, P\u00e9rez-Gracia JL, S\u00e1nchez-Arr\u00e1ez A, et al. Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy. Ann Oncol. 2017;28:xii44\u201355.","journal-title":"Ann Oncol"},{"key":"565_CR23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/eji.201444651","volume":"45","author":"M Mart\u00ednez-L\u00f3pez","year":"2015","unstructured":"Mart\u00ednez-L\u00f3pez M, Iborra S, Conde-Garrosa R, Sancho D. Batf3-dependent CD103 + dendritic cells are major producers of IL-12 that drive local Th1 immunity against Leishmania major infection in mice. Eur J Immunol. 2015;45:119\u201329.","journal-title":"Eur J Immunol"},{"key":"565_CR24","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ccell.2014.09.006","volume":"26","author":"B Ruffell","year":"2014","unstructured":"Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Ho CMT, Pryer N, et al. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in Intratumoral dendritic cells. Cancer Cell. 2014;26:623\u201337.","journal-title":"Cancer Cell"},{"key":"565_CR25","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1126\/science.1164206","volume":"322","author":"K Hildner","year":"2008","unstructured":"Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, Kohyama M, et al. Batf3 deficiency reveals a critical role for CD8 + dendritic cells in cytotoxic T cell immunity. Science. 2008;322:1097\u2013100.","journal-title":"Science"},{"key":"565_CR26","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","volume":"26","author":"ML Broz","year":"2014","unstructured":"Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell. 2014;26:638\u201352.","journal-title":"Cancer Cell"},{"key":"565_CR27","doi-asserted-by":"publisher","first-page":"e1188244","DOI":"10.1080\/2162402X.2016.1188244","volume":"5","author":"M Azuma","year":"2016","unstructured":"Azuma M, Takeda Y, Nakajima H, Sugiyama H, Ebihara T, Oshiumi H, et al. Biphasic function of TLR3 adjuvant on tumor and spleen dendritic cells promotes tumor T cell infiltration and regression in a vaccine therapy. Oncoimmunology. 2016;5:e1188244.","journal-title":"Oncoimmunology"},{"key":"565_CR28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1158\/2159-8290.CD-15-0510","volume":"6","author":"AR Sanchez-Paulete","year":"2016","unstructured":"Sanchez-Paulete AR, Cueto FJ, Martinez-Lopez M, Labiano S, Morales-Kastresana A, Rodriguez-Ruiz ME, et al. Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells. Cancer Discov. 2016;6:71\u20139.","journal-title":"Cancer Discov"},{"key":"565_CR29","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","volume":"44","author":"H Salmon","year":"2016","unstructured":"Salmon H, Idoyaga J, Rahman A, Leboeuf M, Remark R, Jordan S, et al. Expansion and activation of CD103 + dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity. 2016;44:924\u201338.","journal-title":"Immunity"},{"key":"565_CR30","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ccell.2016.06.003","volume":"30","author":"EW Roberts","year":"2016","unstructured":"Roberts EW, Broz ML, Binnewies M, Headley MB, Nelson AE, Wolf DM, et al. Critical role for CD103 + \/CD141 + dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell. 2016;30:324\u201336.","journal-title":"Cancer Cell"},{"key":"565_CR31","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","volume":"31","author":"S Spranger","year":"2017","unstructured":"Spranger S, Dai D, Horton B, Gajewski TF. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell. 2017;31:711\u2013723.e4.","journal-title":"Cancer Cell"},{"key":"565_CR32","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","volume":"172","author":"JP B\u00f6ttcher","year":"2018","unstructured":"B\u00f6ttcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S, et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting Cancer immune control. Cell. 2018;172:1022\u20131037.e14.","journal-title":"Cell"},{"key":"565_CR33","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity. Nature. 2015;523:231\u20135.","journal-title":"Nature"},{"key":"565_CR34","first-page":"3239","volume":"60","author":"N Mach","year":"2000","unstructured":"Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M, Dranoff G. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res. 2000;60:3239\u201346.","journal-title":"Cancer Res"},{"key":"565_CR35","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nature07750","volume":"458","author":"D Sancho","year":"2009","unstructured":"Sancho D, Joffre OP, Keller AM, Rogers NC, Mart\u00ednez D, Hernanz-Falc\u00f3n P, et al. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature. 2009;458:899\u2013903.","journal-title":"Nature"},{"key":"565_CR36","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.immuni.2013.07.004","volume":"39","author":"K Palucka","year":"2013","unstructured":"Palucka K, Banchereau J. Dendritic-cell-based therapeutic Cancer vaccines. Immunity. 2013;39:38\u201348.","journal-title":"Immunity"},{"key":"565_CR37","doi-asserted-by":"publisher","first-page":"588","DOI":"10.3389\/fimmu.2015.00588","volume":"6","author":"AD Garg","year":"2015","unstructured":"Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, et al. Molecular and translational classifications of DAMPs in immunogenic cell death. Front Immunol. 2015;6:588.","journal-title":"Front Immunol"},{"key":"565_CR38","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","volume":"17","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi L, Buqu\u00e9 A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17:97\u2013111.","journal-title":"Nat Rev Immunol"},{"key":"565_CR39","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini J-L, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13:54\u201361.","journal-title":"Nat Med"},{"key":"565_CR40","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","volume":"13","author":"L Apetoh","year":"2007","unstructured":"Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4\u2013dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050\u20139.","journal-title":"Nat Med"},{"key":"565_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/cddis.2015.129","volume":"6","author":"N Werthm\u00f6ller","year":"2015","unstructured":"Werthm\u00f6ller N, Frey B, Wunderlich R, Fietkau R, Gaipl US. Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide- and T-cell-dependent manner. Cell Death Dis. 2015;6:1\u201311.","journal-title":"Cell Death Dis"},{"key":"565_CR42","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1002\/eji.1830201111","volume":"20","author":"J Nikoli\u0107-\u017dugi\u0107","year":"1990","unstructured":"Nikoli\u0107-\u017dugi\u0107 J, Carbone FR. The effect of mutations in the MHC class I peptide binding groove on the cytotoxic T lymphocyte recognition of the kb-restricted ovalbumin determinant. Eur J Immunol. 1990;20:2431\u20137.","journal-title":"Eur J Immunol"},{"key":"565_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/0471142735.im2001s39","volume-title":"B16 as a mouse model for human melanoma. In: current protocols in immunology","author":"WW Overwijk","year":"2001","unstructured":"Overwijk WW, Restifo NP. B16 as a mouse model for human melanoma. In: current protocols in immunology. Hoboken: Wiley; 2001. p. Unit 20 1"},{"key":"565_CR44","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3389\/fimmu.2014.00149","volume":"5","author":"CM Fehres","year":"2014","unstructured":"Fehres CM, Unger WWJ, Garcia-Vallejo JJ, van Kooyk Y. Understanding the biology of antigen cross-presentation for the design of vaccines against Cancer. Front Immunol. 2014;5:149.","journal-title":"Front Immunol"},{"key":"565_CR45","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.immuni.2012.03.008","volume":"36","author":"S Ahrens","year":"2012","unstructured":"Ahrens S, Zelenay S, Sancho D, Han\u010d P, Kj\u00e6r S, Feest C, et al. F-actin is an evolutionarily conserved damage-associated molecular pattern recognized by DNGR-1, a receptor for dead cells. Immunity. 2012;36:635\u201345.","journal-title":"Immunity"},{"key":"565_CR46","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.immuni.2014.02.004","volume":"40","author":"TS Kim","year":"2014","unstructured":"Kim TS, Gorski SA, Hahn S, Murphy KM, Braciale TJ. Distinct dendritic cell subsets dictate the fate decision between effector and memory CD8+ T cell differentiation by a CD24-dependent mechanism. Immunity. 2014;40:400\u201313.","journal-title":"Immunity"},{"key":"565_CR47","doi-asserted-by":"publisher","first-page":"486","DOI":"10.4161\/cbt.1.5.161","volume":"1","author":"J Dong","year":"2002","unstructured":"Dong J, McPherson CM, Stambrook PJ. Flt-3 ligand: a potent dendritic cell stimulator and novel antitumor agent. Cancer Biol Ther. 2002;1:486\u20139.","journal-title":"Cancer Biol Ther"},{"key":"565_CR48","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1126\/science.aad0395","volume":"350","author":"N Yatim","year":"2015","unstructured":"Yatim N, Jusforgues-Saklani H, Orozco S, Schulz O, Da Silva RB, Reis E, Sousa C, et al. RIPK1 and NF-kB signaling in dying cells determines cross-priming of CD8+ T cells. Science. 2015;350:328\u201334.","journal-title":"Science"},{"key":"565_CR49","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1172\/JCI60660","volume":"122","author":"S Iborra","year":"2012","unstructured":"Iborra S, Izquierdo HM, Mart\u00ednez-L\u00f3pez M, Blanco-Men\u00e9ndez N, Reis e Sousa C, Sancho D. The DC receptor DNGR-1 mediates cross-priming of CTLs during vaccinia virus infection in mice. J Clin Invest. 2012;122:1628\u201343.","journal-title":"J Clin Invest"},{"key":"565_CR50","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/eji.201546023","volume":"46","author":"M-C Chiang","year":"2016","unstructured":"Chiang M-C, Tullett KM, Lee YS, Idris A, Ding Y, McDonald KJ, et al. Differential uptake and cross-presentation of soluble and necrotic cell antigen by human DC subsets. Eur J Immunol. 2016;46:329\u201339.","journal-title":"Eur J Immunol"},{"key":"565_CR51","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.immuni.2016.08.019","volume":"45","author":"S Iborra","year":"2016","unstructured":"Iborra S, Mart\u00ednez-L\u00f3pez M, Khouili SC, Enamorado M, Cueto FJ, Conde-Garrosa R, et al. Optimal generation of tissue-resident but not circulating memory T cells during viral infection requires Crosspriming by DNGR-1 + dendritic cells. Immunity. 2016;45:847\u201360.","journal-title":"Immunity"},{"key":"565_CR52","doi-asserted-by":"publisher","first-page":"16073","DOI":"10.1038\/ncomms16073","volume":"8","author":"M Enamorado","year":"2017","unstructured":"Enamorado M, Iborra S, Priego E, Cueto FJ, Quintana JA, Mart\u00ednez-Cano S, et al. Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8+ T cells. Nat Commun. 2017;8:16073.","journal-title":"Nat Commun"},{"key":"565_CR53","doi-asserted-by":"publisher","first-page":"13720","DOI":"10.1038\/ncomms13720","volume":"7","author":"D Laoui","year":"2016","unstructured":"Laoui D, Keirsse J, Morias Y, Van Overmeire E, Geeraerts X, Elkrim Y, et al. The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity. Nat Commun. 2016;7:13720.","journal-title":"Nat Commun"},{"key":"565_CR54","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrc3973","volume":"15","author":"I Melero","year":"2015","unstructured":"Melero I, Berman DM, Aznar MA, Korman AJ, P\u00e9rez Gracia JL, Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. 2015;15:457\u201372.","journal-title":"Nat Rev Cancer"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0565-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0565-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0565-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T13:44:05Z","timestamp":1601041445000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0565-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,8]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["565"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0565-5","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,8]]},"assertion":[{"value":"22 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The local ethics committee approved all animal studies. All animal procedures conformed to EU Directive 2010\/63EU and Recommendation 2007\/526\/EC regarding the protection of animals used for experimental and other scientific purposes, enforced in Spanish law under Real Decreto 1201\/2005.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"IM reports receiving commercial research grants from BMS and ROCHE and serves as a consultant\/advisory board member for BMS, Merck-Serono, Roche-Genentech, Genmab, Incyte, Bioncotech, Tusk, Molecular partners F-STAR, Alligator and AstraZeneca. The authors have no additional financial interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"100"}}